INTELLIA THERAPEUTICS INC (NTLA)
Health Care · Biotechnology (Gene Editing) · NASDAQ
Intellia Therapeutics is a genome editing pioneer developing CRISPR/Cas9-based, potentially curative in vivo therapies for genetic diseases.
What INTELLIA THERAPEUTICS INC does
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing curative genome editing treatments. The company utilizes a modular platform based on CRISPR/Cas9 technology to create in vivo therapies for severe diseases, with a primary focus on liver-directed treatments. Its lead programs include therapies for hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis.
Themes: CRISPR gene editing, genomic medicine, rare disease therapies, in vivo gene therapy
Fundamentals
- Price$11.84 as of 2026-10-20 close
- Market cap$1.7B as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return-57.7% 2025-10-20 close $27.98 → 2026-10-20 close $11.84
- P/En/a negative earnings
- Net margin-609.9% FY2025, SEC XBRL
- ROE-61.5% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+16.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+9.1% SEC XBRL
- Beta1.66 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How NTLA compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $8M | -$113M | -$107M | -$0.80 | -$83M† | $2M† |
| Q1 FY2026 2026-03-31 | $15M | -$101M | -$96M | -$0.81 | -$117M | $79000 |
| Q4 FY2025 2025-12-31 | $23M† | -$99M† | -$96M† | -$0.82† | -$69M† | $126000† |
| Q3 FY2025 2025-09-30 | $14M | -$111M | -$101M | -$0.92 | -$77M† | $29000† |
| Q2 FY2025 2025-06-30 | $14M | -$110M | -$101M | -$0.98 | -$100M† | $239000† |
| Q1 FY2025 2025-03-31 | $17M | -$121M | -$114M | -$1.10 | -$149M | $735000 |
| Q4 FY2024 2024-12-31 | $13M† | -$136M† | -$129M† | -$1.26† | -$85M† | $981000† |
| Q3 FY2024 2024-09-30 | $9M | -$145M | -$136M | -$1.34 | -$85M† | $1M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$106M
- Short-term investments$332M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How INTELLIA THERAPEUTICS INC looks technically
INTELLIA THERAPEUTICS INC (NTLA) is trading 8.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 27 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day low about 4 trading days ago. It is 58.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 8.3% below its 200-day average, the long-term trend line — a long-term downtrend | -8.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.25 | $12.25 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.92 | $12.92 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 13.27. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 27 trading days ago — a "death cross", a bearish long-term signal | 27 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 47.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($10.91 to $13.27) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 39.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $28.25 | $28.25 |
|---|---|---|
| From the 52-week high | it is 58.1% below its 52-week high (its highest price of the past year) | -58.1% |
| Above the 52-week low | it is 48.9% above its 52-week low (its lowest price of the past year) | +48.9% |
| Below the 52-week high | it is 58.1% below its highest point of the past year | 58.1% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $202.73 (set on 2021-06-30) | $202.73 |
| Given back of the 52-week move | over the past year its closes ranged ($8.04 to $27.98), and it has recovered roughly a quarter of its fall from last year’s high — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.36 to $21.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.1% |
| From the all-time high | it is 94.2% below its all-time high | -94.2% |
| Nearest price level | it is trading 1.0% above a support level at $11.72 — a price it turned at five times since 2025-10-30, most recently on 2026-06-11. Since 2024-10-21 it has 7 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $5.90 (set on 2025-04-07) | $5.90 |
| Above the all-time low | it is 100.7% above its all-time low | +100.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7407 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7407 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.09 and $12.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.09 – $12.04 – $12.99 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (8.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.62× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.3% |
|---|---|---|
| Open gap | it gapped 2.2% below the previous close 5 sessions ago and has not traded back through the level it left behind at 12.58 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.2% |
| Gap filled | a 2.3% gap up opened on 2026-10-16 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +4.41% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.4 percentage points (the stock lost 2.5% while the market gained 1.0%) | -3.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.8 percentage points (the stock gained 8.4% while the market gained 3.6%) | +4.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 30.7 percentage points (the stock lost 22.2% while the market gained 8.5%) | -30.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 72.2 percentage points (the stock lost 57.7% while the market gained 14.6%) | -72.3% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.1% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 15.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -5.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $13.12 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -9.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $12.21 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -3.0% |
Price levels it has turned at before
NTLA last closed at $11.84 on 2026-10-20. Since 2024-10-21 it has turned at 7 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.72 | Support | 1.0% below the last close | turned there five times · 2025-10-30 to 2026-06-11 |
| $11.36 | Support | 4.1% below the last close | turned there five times · 2024-12-31 to 2026-09-28 |
| $12.51 | Resistance | 5.6% above the last close | turned there twice · 2025-09-03 to 2026-03-13 |
| $10.91 | Support | 7.8% below the last close | turned there twice · 2025-09-10 to 2026-02-05 |
| $12.88 | Resistance | 8.8% above the last close | turned there three times · 2024-11-20 to 2026-09-22 |
| $13.30 | Resistance | 12.4% above the last close | turned there twice · 2025-01-07 to 2026-10-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $13.27.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 3 trading days, since 2026-10-16.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.35 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$23.11 range $8.00 – $61.00; median $16.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NTLA
- Consensus EPS estimate-$0.7856 next reporting period, as of 2026-10-18
- Estimate change, 30 days+$0.00311 from -$0.7887, on 2026-09-13, 35-day window
- Readings revised upward33% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High reliance on successful clinical trial outcomes and FDA regulatory approvals for lead programs.","Significant historical operating losses and a requirement for additional capital to fund operations beyond 2028.","Complex intellectual property landscape involving CRISPR technology and potential for patent disputes."]
What changed in the latest 10-Q
AI-assisted comparison of NTLA's 10-Q filed 2026-05-11 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-11) adds: 'including the ability to successfully complete the filing of a biologics license application ("BLA") or comparable marketing application for lonvo-z in the second half of 2026, receive approval to market lonvo-z, and launch lonvo-z in the U.S. in the first half of 2027' in the lonvo-z forward-looking statement
- Newer filing (2026-05-11) adds: 'the ability to resume dosing in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials following removal of the clinical hold placed by the U.S. Food and Drug Administration ("FDA") on their Investigational New Drug ("IND") applications' in the nex-z forward-looking statement
- Newer filing (2026-05-11) adds: 'including our ability to fund our ongoing operating expenses and capital expenditure requirements at least into 2028' to the financing risk factor bullet point
- Newer filing (2026-05-11) adds: 'In April 2026, we reported positive topline data from the global Phase 3 HAELO clinical trial of lonvo-z in HAE, and preparations are underway for the planned commercial launch of lonvo-z in the first hal' in Management Overview section
- Newer filing (2026-05-11) describes company as 'a leading biopharmaceutical company' rather than 'a leading clinical-stage gene editing company'
- Removed:
- Older filing (2025-11-06) language removed: 'also referred to as NTLA-2002' replaced with 'previously referred to as NTLA-2002' for lonvo-z
- Older filing (2025-11-06) language removed: 'also referred to as NTLA-2001' replaced with 'previously referred to as NTLA-2001' for nex-z
- Older filing (2025-11-06) removed: 'including the ability to successfully complete our global HAELO Phase 3 study, generate results supporting the potential of lonvo-z to achieve lifelong control of HAE attacks after a one-time treatment, report topline data from the HAELO Phase 3 trial by mid-2026' from lonvo-z forward-looking statement
- Older filing (2025-11-06) removed: 'including the ability to resume dosing and screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials by resolving the clinical hold placed by the U.S. Food and Drug Administration ("FDA") on the Investigational New Drug ("IND") applications for these trials' from nex-z forward-looking statement
- Older filing (2025-11-06) removed: detailed Management Overview describing clinical-stage company focus, CRISPR/Cas9 explanation, in vivo and ex vivo applications, and modular platform discussion
- Reworded:
- Lonvo-z bullet point shifted from describing clinical trial completion and filing strategy to describing commercial launch execution strategy (newer filing reflects post-Phase 3 data stage)
- Nex-z bullet point shifted from describing hold resolution strategy to describing resumption of dosing following removal of clinical hold (newer filing reflects different FDA interaction stage)
- Company self-description changed from 'clinical-stage gene editing company' to 'leading biopharmaceutical company' (newer filing reflects advancement toward commercialization)
- Financing risk factor changed from general 'needs for additional financing' to 'including our ability to fund our ongoing operating expenses and capital expenditure requirements at least into 2028' (newer filing adds specific funding runway disclosure)
- Notes:
- Newer filing text appears truncated at end of Management Overview section ('first hal')
- Older filing text also appears truncated at end of Management Overview section ('alon')
- Page number changed from 22 (older) to 19 (newer), likely due to document length differences
Risk Factors
- Added:
- New bullet point added to Summary: 'Our business may be adversely affected if we are unable to successfully file and obtain approval of our biologics license application ("BLA") for lonvoguran ziclumeran ("lonvo-z") for the treatment of patients with hereditary angioedema ("HAE") or, following such approval, we are unable to successfully launch lonvo-z for the treatment of patients of HAE.' (filed 2026-05-11)
- New bullet point added to Summary: 'Following the lifting of the clinical hold that the United States Food and Drug Administration ("FDA") placed on our investigational new drug ("IND") applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran ("nex-z") for the treatment of patients with transthyretin ("ATTR") amyloidosis with cardiomyopathy ("ATTR-CM") and hereditary ATTR amyloidosis with polyneuropathy ("ATTRv-PN"), respectively, we are resuming, and intend to successfully complete, the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials. Our business may be adversely affected if the clinical trials are not resumed in a timely manner, or if other regulatory or patient safety concerns lead to additional delays.' (filed 2026-05-11)
- Asterisk (*) notation added before 'CRISPR genome editing technology has only recently been clinically validated for human therapeutic use.' in Risks Related to Preclinical and Clinical Development section (filed 2026-05-11)
- Asterisk (*) notation added before 'The approaches we are taking to discover and develop novel therapeutics using CRISPR gene editing and our other core technologies are unproven and may never lead to marketable products.' (filed 2026-05-11)
- Removed:
- Bullet point removed from Summary: 'Our investigational new drug ("IND") applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for patients with transthyretin ("ATTR") amyloidosis with cardiomyopathy ("ATTR-CM") and hereditary ATTR amyloidosis with polyneuropathy ("ATTRv-PN"), respectively, have been placed on clinical hold by the United States Food and Drug Administration ("FDA"). At this time, we have not received the FDA's clinical hold letter. We will need to resolve the clinical hold with the FDA in order to resume dosing and screening and successfully complete our global Phase 3 studies for ATTR amyloidosis. Our business may be adversely affected if the clinical hold is not resolved in a timely manner or at all, or if other regulatory or patient safety concerns lead to additional delays. We cannot guarantee that we will be able to address the FDA's concerns in order to resolve the clinical hold.' (filed 2025-11-06)
- Bullet point removed from Summary: 'If we experience delays or difficulties in the enrollment of patients in clinical trials, including as a result of the clinical hold on the IND applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran ("nex-z", also referred to as NTLA-2001), our ability to complete clinical trials or our receipt of necessary regulatory approvals could be delayed or prevented.' (filed 2025-11-06)
- Reworded:
- Reference to 'Annual Report on Form 10-K for the year ended December 31, 2024' changed to 'Annual Report on Form 10-K for the year ended December 31, 2025' (filed 2026-05-11)
- In Risks Related to Preclinical and Clinical Development section: 'developing novel therapeutics utilizing CRISPR genome editing technology' changed to 'developing novel therapeutics utilizing CRISPR gene editing technology and our other core technologies' (filed 2026-05-11)
- In Risks Related to Preclinical and Clinical Development section: 'using CRISPR systems' changed to 'using CRISPR technology, as well as our other core technologies,' (filed 2026-05-11)
- In Risks Related to Preclinical and Clinical Development section: 'The approaches we are taking to discover and develop novel therapeutics using CRISPR systems' changed to 'The approaches we are taking to discover and develop novel therapeutics using CRISPR gene editing and our other core technologies' (filed 2026-05-11)
- Notes:
- The newer filing text appears to be truncated mid-sentence at the end of the provided excerpt, limiting full assessment of all changes
- The older filing text is also truncated mid-sentence, which may affect completeness of comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 1 sell ($23170) — 1 selling insider
- Last 90 days · read to 2026-10-160 buys · 3 sells ($309989) — 2 selling insiders
- Last 180 days · read to 2026-10-160 buys · 6 sells ($529739) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-02. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NTLA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding NTLA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 49,270,356
- Reported value $833,654,426
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NTLA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NTLA had 45,110,513 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
NTLA had 32.2% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.47 days to cover at the same settlement.
- Reported short interest (shares) 45,110,513
- Short interest (% of shares outstanding) 32.2%
- Prior settlement (shares) 46,681,609
- Reported change -3.37%
- Days to cover (reported) 9.47
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDIT)
- Beam Therapeutics (BEAM)
- Alnylam Pharmaceuticals (ALNY)
- BridgeBio Pharma (BBIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NTLA vs…
NTLA ranks in…
Frequently asked questions
What does INTELLIA THERAPEUTICS INC (NTLA) do?
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing curative genome editing treatments. The company utilizes a modular platform based on CRISPR/Cas9 technology to create in vivo therapies for severe diseases, with a primary focus on liver-directed treatments. Its lead programs include therapies for hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis.
What sector is INTELLIA THERAPEUTICS INC (NTLA) in?
INTELLIA THERAPEUTICS INC (NTLA) is classified in the Health Care sector. Its industry is Biotechnology (Gene Editing). It trades on NASDAQ.
Who are INTELLIA THERAPEUTICS INC's (NTLA) competitors?
Notable peers of INTELLIA THERAPEUTICS INC (NTLA) include CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, Alnylam Pharmaceuticals and BridgeBio Pharma. This peer set is informational only — not financial advice.
Is INTELLIA THERAPEUTICS INC (NTLA) overbought or oversold right now?
INTELLIA THERAPEUTICS INC (NTLA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NTLA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.